EXACT SCIENCES CORPORATION

(EXAS)
  Report
Delayed Nasdaq  -  04:00 2022-08-12 pm EDT
42.71 USD   +0.83%
08/10TRANSCRIPT : Exact Sciences Corporation Presents at UBS Genomics 2.0 and Medtech Innovations Summit 2022, Aug-10-2022 01:00 PM
CI
08/04WALL STREET STOCK EXCHANGE : Still seeing the glass half full
MS
08/04ANALYST RECOMMENDATIONS : Illinois Tool Works, Eaton, Marathon Petroleum, Microchip Technology, DuPont de Nemours...
MS
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Exact Sciences : Purchase Agreement - Form 8-K

06/30/2022 | 07:43am EDT


1.01 Entry into a Material Definitive Agreement.
On June 29, 2022, Exact Sciences Corporation (the "Company"), through a wholly-owned special purpose entity, Exact Receivables LLC ("Exact Receivables"), entered into an accounts receivable securitization program (the "Securitization Facility") with PNC Bank, National Association ("PNC"), as administrative agent, with a scheduled maturity date of June 29, 2024. The Securitization Facility provides Exact Receivables with up to $150.0 million of borrowing capacity, subject to maintaining certain borrowing base requirements, by collateralizing the customer accounts receivable of Exact Sciences Laboratories, LLC and Genomic Health, Inc.

PNC serves as the lender pursuant to a Loan Agreement with the Company dated November 5, 2021, under which a revolving line of credit of up to $150.0 million is available to the Company, until a scheduled termination date of November 5, 2023.

On June 29, 2022, Exact Receivables borrowed $50.0 million under the Securitization Facility.

Outstanding loans under the Securitization Facility accrue interest at a rate equal to a daily SOFR rate, a term SOFR rate or a base rate, in any case, plus an applicable margin. Additionally, Exact Receivables will pay certain fees to the agents and the lenders under the Securitization Facility.

The Securitization Facility contains certain customary representations, warranties, affirmative covenants and negative covenants, subject to certain cure periods in some cases, including the eligibility of the receivables, as well as customary reserve requirements, events of default, termination events, and servicer defaults. The Securitization Facility termination events permit the lenders to terminate the Receivables Financing Agreement upon the occurrence of certain specified events, including, among others, failure by Exact Receivables to pay amounts when due, certain defaults on other material indebtedness, certain judgments, a change of control, certain events negatively affecting the overall credit quality of transferred receivables and bankruptcy and insolvency events.

The Securitization Facility consists of, among other agreements, (i) a Receivables Financing Agreement (the "Receivables Financing Agreement") among Exact Receivables, PNC, as administrative agent, and the lenders and other parties party thereto, (ii) a Receivables Purchase Agreement (the "Company Purchase Agreement") among the Company and certain subsidiaries of the Company and (iii) a Receivables Purchase Agreement (the "Borrower Purchase Agreement") among Exact Receivables and the Company. The foregoing descriptions of the Receivables Financing Agreement, the Company Purchase Agreement and the Borrower Purchase Agreement do not purport to be complete and are qualified in their entirety by reference to the full text of such agreements, copies of which are filed herewith as Exhibit 10.1, Exhibit 10.2, and Exhibit 10.3, respectively, and the terms of which are incorporated herein by reference.

2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth in Item 1.01 above is incorporated by reference into this Item 2.03.

2

9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Exhibit Description
10.1*
Receivables Financing Agreement dated as of June 29, 2022 by and among Exact Receivables LLC, as borrower, the persons from time to time party thereto as lenders and group agents, PNC Bank, National Association, as administrative agent, Exact Sciences Laboratories, LLC, as initial servicer, and PNC Capital Markets, LLC, as structuring agent
10.2*
Receivables Purchase Agreement dated as of June 29, 2022 by and among Exact Sciences Corporation, as seller, Exact Sciences Laboratories, LLC, as initial servicer, and Exact Receivables LLC, as buyer
10.3*
Receivables Purchase Agreement dated as of June 29, 2022 by and among the entities from time to time party thereto as originators, Exact Sciences Laboratories, LLC, as initial servicer, and Exact Sciences Corporation, as buyer
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
______________
*Certain annexes to these agreements have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally to the Securities and Exchange Commission a copy of any omitted annex upon request.
3

Disclaimer

EXACT Sciences Corporation published this content on 30 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 June 2022 11:42:05 UTC.


© Publicnow 2022
All news about EXACT SCIENCES CORPORATION
08/10TRANSCRIPT : Exact Sciences Corporation Presents at UBS Genomics 2.0 and Medtech Innovatio..
CI
08/04WALL STREET STOCK EXCHANGE : Still seeing the glass half full
MS
08/04ANALYST RECOMMENDATIONS : Illinois Tool Works, Eaton, Marathon Petroleum, Microchip Techno..
MS
08/03Craig Hallum Lowers Exact Sciences Price Target to $60 From $81, Maintains Buy Rating
MT
08/03BTIG Adjusts Price Target on Exact Sciences to $70 From $100, Reiterates Buy Rating
MT
08/03Cowen Adjusts Price Target on Exact Sciences to $67 From $83, Keeps Outperform Rating
MT
08/03Baird Adjusts Price Target on Exact Sciences to $75 From $90, Keeps Outperform Rating
MT
08/03Raymond James Adjusts Price Target on Exact Sciences to $70 From $80, Keeps Outperform ..
MT
08/03Citigroup Adjusts Price Target on Exact Sciences to $50 From $65, Maintains Neutral Rat..
MT
08/03MDxHealth Agrees to Buy Exact Sciences' Prostate Cancer Unit for Up to $100 Million
MT
More news
Analyst Recommendations on EXACT SCIENCES CORPORATION
More recommendations
Financials (USD)
Sales 2022 2 013 M - -
Net income 2022 -757 M - -
Net Debt 2022 1 950 M - -
P/E ratio 2022 -10,1x
Yield 2022 -
Capitalization 7 558 M 7 558 M -
EV / Sales 2022 4,72x
EV / Sales 2023 4,21x
Nbr of Employees 6 460
Free-Float 99,1%
Chart EXACT SCIENCES CORPORATION
Duration : Period :
Exact Sciences Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EXACT SCIENCES CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 17
Last Close Price 42,71 $
Average target price 70,63 $
Spread / Average Target 65,4%
EPS Revisions
Managers and Directors
Kevin T. Conroy Chairman, President & Chief Executive Officer
Jeffrey Thomas Elliott Executive VP, Chief Operating & Financial Officer
Sandra Statz Senior VP-Clinical & Regulatory Affairs
Gary Frings Chief Information Officer
Paul J. Limburg Co-Chief Medical Officer
Sector and Competitors